Erik Holmlin, PhD
President and Chief Executive Officer

Erik Holmlin is a dynamic leader with more than two decades of experience developing innovative solutions and companies in the life sciences and health care industries.

Read More

Erik’s experience includes positions at GenVault Corporation (CEO), Exiqon A/S (CCO) and Becton Dickinson (vice president of marketing and development). In 2001, Erik led the formation and financing efforts of GeneOhm Sciences, Inc. and orchestrated the company’s acquisition by Becton Dickinson in 2006. He also served as an entrepreneur in residence (EIR) at leading life-science venture capital firm Domain Associates, LLC.

Erik was a National Institutes of Health postdoctoral fellow at Harvard University and a National Science Foundation predoctoral fellow at the California Institute of Technology, Pasadena (Caltech). He holds a PhD in chemistry from Caltech and MBAs from UC Berkeley and Columbia University.

Read Less
Christopher Stewart
Chief Financial Officer

Christopher Stewart is a seasoned leader with over 20 years of experience spanning finance, accounting, and strategic planning for many commercial-stage operating businesses.

Read More

Chris has served in a number of executive roles in both private and public companies as Controller, V.P. of Finance and CFO. He also has experience with major financing events, acquisitions, and scaling revenues in high-growth tech companies. He joined Bionano from Tesla, where he served as Head of the Maxwell Ultracapacitors business unit after Maxwell Technology was acquired by Tesla. Chris received his Master of Science in Business Administration and Finance from University of Southern California and his MBA in Finance from Carnegie Mellon University.

Read Less
Mark Oldakowski
Chief Operating Officer

Mark Oldakowski has a 20-year history of success in the development of systems for the life sciences and medical device industries.

Read More

Prior to joining Bionano Genomics, Mark led a global team at Brooks Life Science Systems in the development of sample analyzers, high-throughput screening solutions, and chemical storage and biobank systems. Prior to his time at Brooks, Mark was with Affymetrix, where he launched the array platform that is widely used today for GWAS and other genomics applications. Mark also spent time at Siemens Healthcare Diagnostics on the development of equipment for diagnostic core labs. During his 13 years at Life Technologies (formerly Applied Biosystems) he held various levels of responsibility in the development of systems for real-time PCR, sequencing and sample preparation. Mark holds a bachelor’s degree in electrical engineering and a master’s degree in computer and systems engineering from Rensselaer Polytechnic Institute in New York.

Read Less
Richard Shippy
Chief Business Officer

Richard joined Bionano as Chief Business Officer in June 2021.  Richard has over two decades of experience in life sciences, focused on healthcare.

Read More

He co-founded and led commercial operations at Cradle Genomics, which is the leader in developing non-invasive prenatal tests based on analysis of intact cells. Prior to Cradle, he was the Senior Director of Strategic Product Marketing in Reproductive and Genetic Health at Illumina, where he led the product strategy and management for preimplantation testing, prenatal testing, chromosomal microarray (CMA) and postnatal genetic disease testing. As a Senior Director of Product Marketing at Affymetrix, he partnered with the global cytogenomics community to launch CytoScan, the market leading CMA product and the only FDA cleared whole genome copy number analysis platform. He also oversaw the launch of OncoScan for solid tumor analysis.

Read Less
Alka Chaubey, PhD, FACMG
Chief Medical Officer

Alka Chaubey is double board-certified in clinical cytogenetics/genomics and clinical molecular genetics/genomics by the American Board of Medical Genetics and Genomics (ABMGG).

Read More

Previously, she was the Head of Cytogenomics at PerkinElmer Genomics, where Dr. Chaubey led the successful development and launch of several innovative products including the CNGnome test (low-pass whole genome sequencing), and a new FSHD assay utilizing Saphyr. She has also played an integral role on Vanadis team at PerkinElmer in their efforts to bring a new PCR-free NIPT technology to the market. Prior to PerkinElmer Genomics, Dr. Chaubey was the Director of the Cytogenomics Laboratory at the Greenwood Genetic Center, SC, USA. She also holds an academic appointment as the Scientific Director of the Georgia Esoteric and Molecular Laboratory, Scientific Director of the Cytogenetics Laboratory of the Augusta University Medical Center and Adjunct Assistant professor of Pathology of the medical College of Georgia at Augusta University.


Dr. Chaubey serves on the Board of Directors for the Cancer Genomics Consortium and is also the Genetics Subdivision Nominating Committee representative of the Association of Molecular Pathologists (AMP). She originally received her Doctorate degree (PhD) from Guru Nanak Dev University, Amritsar, India and completed her post-doctoral studies at Center for Cellular and Molecular Biology (CCMB), Hyderabad, India, and University of Illinois at Chicago (UIC).

Read Less
Soheil Shams, PhD
Chief Informatics Officer

Dr. Soheil Shams joined Bionano as Chief Informatics Officer in October 2021.

Read More

Prior to joining Bionano, Dr. Shams was founder and general manager of BioDiscovery, Inc., a leading software company for the application of genomics, since 1997. Prior to that, he was a lecturer at UCLA on bioinformatics for several years teaching graduate and undergraduate courses on AI and machine perception in computer science. Dr. Shams received his PhD and MS from USC and has a BS in electrical engineering from CSULB.

Read Less

This website stores cookies on your computer. These cookies are used to collect information about how you interact with our website and allow us to remember you. We use this information in order to improve and customize your browsing experience and for analytics and metrics about our visitors both on this website and other media. To find out more about the cookies we use, see our Privacy Policy.